^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GSK2130579A

    i
    Associations
    News

    Trials

    Company:
    GSK
    Drug class:
    Immunostimulant, Cytotoxic T lymphocyte stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy (NCT01051063)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    11/29/2018
    Initiation :
    12/09/2009
    Primary completion :
    04/26/2016
    Completion :
    04/26/2016
    WT1
    |
    GSK2130579A
    Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) (NCT00725283)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    08/07/2018
    Initiation :
    10/01/2008
    Primary completion :
    06/22/2016
    Completion :
    06/22/2016
    WT1
    |
    GSK2130579A